Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in TEM.
← Back to Free Index

TEM

Analysis as of: 2026-01-28
Tempus AI, Inc.
AI-enabled precision medicine company providing genomic diagnostics plus data/licensing and clinical software products to providers and life sciences companies.
ai healthcare medical devices software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • Third Party Analyst Consensus

Summary

Diagnostics scale funds a higher-margin data platform
A scaled genomics diagnostics engine is increasingly monetized via contracted biopharma data and clinician workflow software. Upside comes from mix-shift and better cash conversion; downside comes from financing and reimbursement permissioning.

Analysis

Thesis
Tempus can compound a diagnostics→data→workflow flywheel: scale in reimbursed testing keeps feeding a growing, higher-value data/licensing + clinician workflow layer, and AI makes the “insight” marginal cost fall—if Tempus converts contract value into repeatable revenue while reducing financing dependence, EV can plausibly 2x+ by 2031.
Last Economy Alignment
It organizes scarce, trusted clinical truth (data rights + workflow distribution) while AI commoditizes analysis; value shifts to dataset access, integration, and habit loops.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.6x (from 5 most recent analyses)
Reasoning
Tempus’ non-linear upside is mix and durability: a scaled lab footprint funds data/licensing and workflow products where AI makes marginal “insight” cheaper, improving gross profit per patient over time. Recent record contracted demand supports the idea that pharma/data revenue can become more renewal-like. The constraint is capital: until cash generation is consistently positive, valuation remains sensitive to financing windows and reimbursement permissioning.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The two binding risks into 2031 are (1) capital access while cash burn persists and (2) reimbursement/coverage permissioning for advanced diagnostics. If Tempus can convert contracted demand into predictable revenue and reduce financing dependence, the risk discount can compress; if not, dilution and multiple compression can dominate even with top-line growth.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Third Party Analyst Consensus

12-Month Price Target
$83.00
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case